BioCentury | Jul 9, 2001
Strategy

Front door, back door

Front door, back door Company Product Status GlaxoSmithKline (GSK; LSE:GSK) Avandia rosiglitazone Marketed Takeda Actos pioglitazone Marketed Biotech Holdings (CDNX:BIO; BIOHF) Diab II Marketed (China) GlaxoSmithKline (GSK; LSE:GSK) GI262570 Phase III Metabolex MBX-102 Preclinical Metabolex...
BC Week In Review | Jul 10, 2000
Clinical News

GI262570: Phase III trial update

Glaxo Wellcome plc (LSE:GLXO; GLX), London, U.K.   SmithKline Beecham plc (LSE:SB; SBH), London, U.K.   Product: GI262570   Business: Pharmaceuticals   Therapeutic category: Receptor agonist   Target: Peroxisome proliferator-activator receptor gamma   Description: Peroxisome...
BC Week In Review | Jun 19, 2000
Clinical News

GI262570: Phase III

In a 376-patient Phase III study, once daily doses of 1-10 mg GI262570 produced a significant improvement from baseline in fasting serum glucose and HbA1c levels at 12 weeks compared to placebo. The 10 mg...
BioCentury | Feb 22, 1999
Tools & Techniques

Inflection points

As news watchers come to realize, seemingly independent events have a way of piling up on themselves and pushing other topics into the background. With the stars thus aligned, it becomes impossible to ignore the...
BioCentury | Dec 14, 1998
Tools & Techniques

Diabetes Pipeline

Diabetes Pipeline Company Product Product type Therapeutic focus Status Ergo Science (ERGO) Ergoset bromocriptine dopamine D2 agonist Regulate glucose metabolism NDA nonapprovable Novo Nordisk NovoRapid short-acting insulin analog Regulate glucose metabolism NDA, MAA submitted SmithKline...
Items per page:
1 - 5 of 5